339986-90-2

339986-90-2 structure

Name: Tucotuzumab
Chemical Name: Tucotuzumab
CAS Number: 339986-90-2
Molecular Formula:
Molecular Weight:
Catalog: Signaling Pathways Immunology/Inflammation Interleukin Related
Create Date: 2023-01-14 17:36:26
Modify Date: 2024-01-15 10:06:30
Tucotuzumab (Anti-EPCAM Recombinant Antibody) is a protein composed of an IgG1 monoclonal antibody specific for the human Epithelial Cell Adhesion Molecule (EpCAM) antigen, linked to two molecules of IL-2. Tucotuzumab is an immunosuppressant and antineoplastic agent[1].

Name	Tucotuzumab

Description	Tucotuzumab (Anti-EPCAM Recombinant Antibody) is a protein composed of an IgG1 monoclonal antibody specific for the human Epithelial Cell Adhesion Molecule (EpCAM) antigen, linked to two molecules of IL-2. Tucotuzumab is an immunosuppressant and antineoplastic agent[1].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Immunology/Inflammation >> Interleukin Related Research Areas >> Inflammation/Immunology
In Vitro	Tucotuzumab 靶向肿瘤并通过 IL-2 应答性免疫细胞刺激抗肿瘤免疫反应，以及通过其 Fc 受体刺激免疫细胞[1]。
In Vivo	Tucotuzumab (75 μg; 瘤内注射; 每日 5 次，每次15 μg (总剂量 75 μg)，各用50 μL PBS; 在第 10 天和第 14 天)，肿瘤生长抑制显著增强，生存率提高[1]。 Animal Model: Female Balb/c mice bearing CT26-KS colon adenocarcinoma[1] Dosage: 75 μg Administration: Intratumoral injection; 5 daily of 15 μg (total dose of 75 μg), each in 50 μL PBS; on days 10 and 14 Result: Resulted in significantly greater tumor growth suppression and enhanced survival.
References	[1]. Erik E Johnson, et al. Radiofrequency ablation combined with KS-IL2 immunocytokine (EMD 273066) results in an enhanced antitumor effect against murine colon adenocarcinoma. Clin Cancer Res. 2009 Aug 1;15(15):4875-84.

No Any Chemical & Physical Properties